Exercise boosts survival rates in cancer patients, study shows
Prior evidence was based on comparing active people with sedentary people, a type of study that can't prove cause and effect. The new study — conducted in Canada, Australia, the United Kingdom, Israel and the United States — compared people who were randomly selected for an exercise program with those who instead received an educational booklet.
Get Love Letters: The Newsletter
A weekly dispatch with all the best relationship content and commentary – plus exclusive content for fans of Love Letters, Dinner With Cupid, weddings, therapy talk, and more.
Enter Email
Sign Up
'This is about as high a quality of evidence as you can get,' said Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology. 'I love this study because it's something I've been promoting but with less strong evidence for a long time.'
Advertisement
The findings were featured Sunday at ASCO's annual meeting in Chicago and published by the New England Journal of Medicine. Academic research groups in Canada, Australia and the U.K. funded the work.
Researchers followed 889 patients with treatable colon cancer who had completed chemotherapy. Half were given information promoting fitness and nutrition. The others worked with a coach, meeting every two weeks for a year, then monthly for the next two years.
Advertisement
Coaches helped participants find ways to increase their physical activity. Many people, including Terri Swain-Collins, chose to walk for about 45 minutes several times a week.
'This is something I could do for myself to make me feel better,' said Swain-Collins, 62, of Kingston, Ontario. Regular contact with a friendly coach kept her motivated and accountable, she said. 'I wouldn't want to go there and say, 'I didn't do anything,' so I was always doing stuff and making sure I got it done.'
After eight years, the people in the structured exercise program not only became more active than those in the control group but also had 28% fewer cancers and 37% fewer deaths from any cause. There were more muscle strains and other similar problems in the exercise group.
'When we saw the results, we were just astounded,' said study co-author Dr. Christopher Booth, a cancer doctor at Kingston Health Sciences Centre in Kingston, Ontario.
Exercise programs can be offered for several thousand dollars per patient, Booth said, 'a remarkably affordable intervention that will make people feel better, have fewer cancer recurrences and help them live longer.'
Researchers collected blood from participants and will look for clues tying exercise to cancer prevention, whether through insulin processing or building up the immune system or something else.
Swain-Collins' coaching program ended, but she is still exercising. She listens to music while she walks in the countryside near her home.
That kind of behavior change can be achieved when people believe in the benefits, when they find ways to make it fun and when there's a social component, said paper co-author Kerry Courneya, who studies exercise and cancer at the University of Alberta. The new evidence will give cancer patients a reason to stay motivated.
Advertisement
'Now we can say definitively exercise causes improvements in survival,' Courneya said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 hours ago
- Medscape
PVEK: New Standard of Care in Rare, Deadly Blood Cancer?
CHICAGO — The antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) yielded high response rates with good durability in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the phase 1/2 CADENZA trial. 'We conclude that PVEK represents a potentially practice-changing paradigm for patients with the rare disease BPDCN,' said study author Naveen Pemmaraju, MD, of MD Anderson Cancer Center in Houston, Texas, during an oral abstract session at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. 'One half of first-line patients treated with PVEK subsequently received stem cell transplant. PVEK treatment had a manageable safety profile, and infusion-related reactions and peripheral edema were resolved with supportive care. No capillary-leak syndrome was observed.' CADENZA enrolled 84 adult patients with CD123-positive BPDCN. Of these patients, 33 were newly diagnosed, and 51 patients had relapsed or refractory (R/R) BPDCN with one, two, or three prior lines of therapy. In the first-line group, 22 patients had de novo disease and 11 had a prior or concomitant hematologic malignancy (PCHM). CADENZA's primary endpoint was the composite rate of complete response (CR) plus CR with minimal skin abnormality (CRc) in the first-line de novo patients. The authors found that 70% of patients achieved the composite CR, while 14% of the patients with R/R disease did. Regarding the overall response rate (ORR), 85% of first-line patients responded to PVEK, while 35% of patients with R/R disease responded. Responses among patients with R/R disease were early and durable (median, 1.4 months and 9.2 months, respectively). PCHM status did not affect overall survival (OS) in first-line patients: Median OS was 16.6 months in both the de novo and PCHM subgroups. The discussant for this study, Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City, told Medscape Medical News that the CADENZA trial supports the use of CD123 as a therapeutic target in BPDCN. He also noted that the current standard of care often causes potentially life-threatening capillary leak syndrome (CLS): 'There were no cases of CLS in this dataset, which means we may have an opportunity to deliver anti-CD123 therapies, with no CLS as a potential side effect.' Rampal also cited PVEK's apparent ability to enable many patients to bridge to stem cell transplant, 'the fundamental prospect in terms of long-term survival provisions with BPDCN.' Following this presentation, Pemmaraju sat down with Medscape Medical News . The following interview has been edited for clarity. Please give us some context on BPDCN and why it is difficult to treat. BPDCN is a rare, aggressive hematologic malignancy primarily involving skin, bone marrow, lymph nodes and the central nervous system. We think there are only 500 BPDCN diagnoses per year in the United States. Current treatment regimens are limited to chemotherapy regimens adapted from AML, ALL, lymphoma, and myeloma. The median age at diagnosis is around 65 years, so many patients are not eligible for intensive chemo or stem cell transplant. CD123 is overexpressed on all BPDCN blasts, making it an ideal target for immunochemotherapy. What is the top takeaway from your presentation? BPDCN has an overall poor prognosis with significant unmet need. Currently, tagraxofusp-erzs is the standard of care and the only approved treatment for BPDCN. PVEK is a new CD123-targeting agent. This novel monotherapy, given once every 3 weeks, had high response rates for frontline patients with BPDCN and was highly durable. Even for patients with R/R disease, whose prognosis is only a few months, PVEK showed some promising activity both in response and durability. Patients with BPDCN are in need of improved frontline therapies to treat their disease, so we're very excited to see this phase 1/2 trial going extremely well in terms of safety and efficacy. The responses we have observed make PVEK a strong candidate as a standard-of-care treatment. What is another important thing you want your colleagues to know about this study? The CADENZA trial enrolled 84 patients, which is a huge number in a rare disease field like ours. I'm proud we were able to achieve a real-world demographic split. That means we had older patients, just like I see in the clinic, and half the patients had skin involvement along with bone marrow. In the relapsed group, the prior therapy had been quite intense. Half of these patients had received chemo, half had received tagraxofusp, and a third had received a transplant. This may be the best study I've ever done in terms of enrolling patients who are truly representative with all the comorbidities, and all the difficulties, you see in clinical practice. You mentioned that PVEK is more patient-friendly than the standard of care. Why is that? PVEK is given once every 3 weeks via an infusion that takes only 30 minutes or less. Many of our other drugs, of course, require a much more intensive schedule that can be difficult for patients, especially when they must be given on an inpatient basis. PVEK can be given outpatient even from the beginning, which is much more convenient for patients. You referred several times to patients' skin lesions. Is that part of the BPDCN disease process or is that a treatment reaction? I want to emphasize this is a BPDCN trait not related to treatment. BPDCN has a predilection for the skin. The vast majority of patients with BPDCN, anywhere from 70% to 90%, will present with skin findings. It's very common for my patients to present with 'just' a skin lesion that turns out to be anything but. Unlike other skin-containing malignancies, BPDCN is a bone marrow blood cancer that can go to an acute leukemia and become acutely life threatening. Let's differentiate that from the cutaneous toxicity very commonly seen in chemo-based regimens. What's ahead in PVEK research? We will keep presenting our data, including at the European Hematological Association and as an ASCO Encore presentation. We hope to submit PVEK to regulatory agencies in the near future. Ultimately, can we combine PVEK with other agents active in the AML and BPDCN space to create a next-generation therapy? Eventually, once we have two active agents for BPDCN, we will need to determine the sequencing of these drugs. What's the natural history of these treated patients? Are they living longer? I think answers to all those questions will come out in the coming year or two. The study was funded by AbbVie. Pemmaraju disclosed having relationships with AbbVie, Aplastic Anemia and MDS International Foundation, Aptitude Health, Astellas Pharma, Blueprint Medicines, Bristol Myers Squibb, CancerNet, CareDx, Celgene, Cimeio Therapeutics, ClearView Healthcare Partners, CTI BioPharma Corp, Curio Science, Dava Oncology, EUSA Pharma, Harborside Press, Imedex, ImmunoGen, Intellisphere, Magdalen Medical Publishing, Medscape, Menarini Group, Neopharm, Novartis, OncLive, Pacylex, Patient Power, Peerview, PharmaEssentia, and Physicians' Education Resource. Rampal reported having ties with AbbVie, Blueprint Medicines, Bristol Myers Squibb/Celgene, Constellation Pharmaceuticals, CTI BioPharma Corp, Disc Medicine, Galecto, Incyte, Karyopharm Therapeutics, Novartis, Pharmaessentia, Promedior, SERVIER, Sierra Oncology, Stemline Therapeutics, Sumitomo Dainippon, and Zentalis.
Medscape
5 hours ago
- Medscape
Luspatercept May Prolong Life in Low-Risk MDS
A new analysis from the COMMANDS trial of erythroid maturation agent luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) shows not only sustained, longer-term benefits over epoetin alfa in providing significantly greater independence from transfusions but also, importantly, a promising trend in reducing disease progression and even improving survival. 'We're starting to see a very significant trend in terms of lower rate of transformation and an improvement in survival for patients treated with luspatercept vs epoetin alfa, and I believe this is the first example of this phenomenon ever reported in low risk MDS,' said first author Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, in Houston, in presenting the findings at American Society of Clinical Oncology (ASCO) 2025 in Chicago. In previously reported primary results, the phase 3, global COMMANDS trial showed luspatercept to be the first therapy to have superiority over erythropoiesis-stimulating agents (ESAs) in transfusion-dependent lower-risk MDS. The findings were especially important, as ESAs had for decades represented the first-line treatment for patients with lower-risk MDS. They were described as leading the way to a 'paradigm shift,' with luspatercept subsequently approved in the first-line and second-line treatment of patients with anemia and low-risk MDS. For the new analysis, Garcia-Manero and colleagues reported the first results regarding longer-term duration of responses, safety, and survival of patients treated for more than 2.5 years. In the study, patients in the luspatercept group (n = 182) received 1.0-1.75 mg/kg subcutaneously every 3 weeks, while those in the epoetin alfa arm (n = 181) received 50-1050 IU/kg, with a maximum dose of 80,000 IU, subcutaneously every week, for at least 24 weeks in both groups. In the new analysis, with a median follow-up of 30.6 months in the luspatercept arm and 28.8 months in the epoetin alfa arm, patients treated with luspatercept vs epoetin alfa had a slower rate of disease progression, with just 2.2% vs 5.6% progressing to higher-risk MDS (hazard ratio [HR], 0.388). While the difference was not significant ( P = .1003), 'what we see is a phenomenon that is emerging that is quite significant in that there is indeed a slower rate of progression in the luspatercept arm vs the epoetin alfa,' Garcia-Manero explained. Of note, however, there was no significant difference between the groups in terms of progression to acute myeloid leukemia (4.9% vs 4.4%). Long-Term Treatment Response In terms of long-term treatment response outcomes, red blood cell transfusion independence of at least 12 weeks was achieved by 76.4% (139/182) of patients on luspatercept vs 55.8% (101/181) of those on epoetin alfa (odds ratio [OR], 2.8; P < .0001). The median cumulative duration of transfusion independence through the end of treatment was 150.0 weeks for luspatercept and 95.1 weeks for epoetin alfa (HR, 0.52; P = .0011). 'The results basically show that patients receiving luspatercept are responding for almost a year longer vs the epoetin alfa,' Garcia-Manero noted. Overall Survival Median overall survival in the intention-to-treat population for luspatercept was not reached, while the rate was 46.7 months for epoetin alfa (HR, 0.86). A regression analysis showed six deaths among 68 patients (8.8%) in the luspatercept arm vs 15 deaths among 55 patients (27.3%) in the epoetin alfa arm (HR, 0.330; P = .02). Importantly, the survival curves begin to separate at 36 months — while the 3-year overall survival rates were 63.8% with luspatercept and 62.2% with epoetin alfa, by 5 years, the overall survival rates were 54.0% and 41.8%, respectively, in favor of luspatercept. 'This is very encouraging data suggesting that those patients treated on the luspatercept arm appear to have a longer longevity that those patients in the epoetin alfa arm,' Garcia-Manero said. Furthermore, subgroup analysis of overall survival based on patient characteristics, including transfusion burden, ring sideroblast activity, and baseline serum erythropoietin (EPO) levels, showed survival favoring luspatercept in all groups. 'I think the data this [subanalysis] data is quite important because there have been some questions in terms of what should be the first-line agent to use in a patient with lower risk disease with a [higher] EPO level,' Garcia-Manero said. 'So if we're looking now looking at an intervention that may be changing the natural history of the disease, I think this is quite significant,' he said. Mechanisms? In terms of the mechanisms that might underlie improvements in survival, Garcia-Manero noted that 'there is emerging data that, for instance, [luspatercept] may modulate not only TGF [transforming growth factor] beta but some other innate immunity pathways that are very important for the behavior of the stem cell in MDS,' he explained. 'Furthermore, the [improved overall survival] may not be just mediated by the need for fewer transfusions or higher hemoglobin levels, but there may be actually some biology behind how these drugs work that could be changing natural history of patients with low-risk MDS,' Garcia-Manero said. Findings Are 'Surprising' Commenting on the study, Pamela Sung, MD, PhD, an assistant professor in the Departments of Medicine and Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, who co-moderated the ASCO session, underscored that the results were not anticipated. 'These findings are a surprise, as there has not been a previous study in low-risk MDS that has shown a potential survival benefit,' Sung said in an interview. 'The reason for this improvement is still under investigation as there were no differences between the groups for transformation to AML' — which may have logically explained differences in survival. Of note, 'there was a clear split of the survival curves beginning at 3 years, which is encouraging that these results will hold with longer follow-up,' she added. The findings underscore that 'luspatercept has sustained responses in terms of RBC transfusion independence,' Sung said. 'Preliminary evidence suggests potential disease-modifying activity and survival benefit in low-risk MDS.' Speaking from the audience, Steven Vogl, MD, an oncologist based in the Bronx, New York, speculated on the potential role of subsequent therapies used after failing on epoetin alfa as increasing deaths in that group. 'If patients fail erythropoietin, they may get more transfusions, and/or more treatment or therapies that can cause, for instance, iron overload,' he noted. 'And [that therapy], which was delayed in the luspatercept group, could have had toxicity and made patients weaker, potentially leading to [higher rates of] death in the epoetin alfa group.' He added that while the cause of death can sometimes be hard to pin down in such studies, 'toxicity isn't so hard.' Garcia-Manero responded, 'I totally agree. The mission for us is to start understanding this a little bit better,' he said. 'I don't think it is as simple as [the luspatercept group] just having fewer transfusions, but I may be wrong. The analysis is ongoing.' The study was sponsored by Celgene and Acceleron Pharma.
Medscape
6 hours ago
- Medscape
Durvalumab Plus FLOT Improves Early Upper-GI Cancer
Adding the immune checkpoint inhibitor durvalumab (Imfinzi) to the standard chemotherapy regimen of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) improved event-free survival (EFS) in patients with resectable, early–stage adenocarcinoma of the upper-gastrointestinal (GI) tract. Experts say these interim results, which were presented by Yelena Janjigian, MD, at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago, make the case for a new standard for treating these cancers. The phase 3 MATTERHORN study 'supports the global adoption of perioperative durvalumab plus FLOT for patients with localized gastric and gastroesophageal junction adenocarcinoma,' said Janjigian of the Memorial Sloan Kettering Cancer Center in New York City at the plenary session of the meeting. The study was published simultaneously in The New England Journal of Medicine . The goal of the study is to address the low cure rates for early-stage gastroesophageal cancer, which remain below 50% with most recurrences occurring within 2 years after surgery, said Janjigian, who is also an author of the new paper. MATTERHORN enrolled 948 people with stage II, III and IVA resectable gastric cancer and gastroesophageal junction cancer, randomizing them to two regimens: Durvalumab 1500 mg plus FLOT before surgery, followed by two cycles of durvalumab 1500 mg every 4 weeks plus FLOT, and then 10 cycles of durvalumab 1500 mg every 4 weeks; or placebo plus FLOT before surgery, and then two cycles of placebo plus FLOT followed by 10 cycles of placebo. Applying Immunotherapy in Early-Stage Disease 'We know that immunotherapy works for stage IV disease in an advanced setting,' Janjigian said at a press conference before the plenary session. 'In metastatic disease, we've been using anti-PD-1 agents for years, but they have not been proven to help patients with early-stage cancer.' In MATTERHORN, patients in the durvalumab group had a 29% relative risk reduction in 2-year EFS, which was the primary endpoint. That risk reduction was 67.4% for the treatment group vs 58.5% for the placebo group ( P <.001), Janjigian said at the plenary session. Because the results are interim, the median EFS with durvalumab was not reached, which means that more than half of the patients in the durvalumab plus FLOT group had not had a cancer recurrence at 2 years. The median EFS for the placebo group was 32.8 months. Among secondary endpoints, 2-year overall survival was 75.7% in the durvalumab group vs 70.4% in the placebo group, a 22% advantage for the former, Janjigian said, but that has not yet reached statistical significance in the interim analysis. The median overall survival rate has not yet been reached because there have not been enough deaths in that group to calculate it, Janjigian told Medscape Medical News . In the placebo group, 2-year overall survival was 47.2 months. 'Survival data will continue to be followed and will be updated,' she said. 'There was a consistent event-free survival benefit with the addition of durvalumab across all subgroups, including patients aged 65 or older, patients enrolled in Asia, and patients with anti-PDL-1 and PDL-1- negative and gastroesophageal junction tumors,' Janjigian said at the plenary session. About 19% of the study participants were in Asia, 53% in Europe, 19% in South America, and 9% in North America. 'All hazard ratio estimates for the subgroups were < 1, reinforcing the consistency and robustness of the treatment effect,' Janjigian said. Safety outcomes were similar in both the durvalumab and placebo groups, Janjigian said. 'Grade 3 and 4 treatment-related adverse events occurred in 60% of patients in the durvalumab arm and 59% in the placebo arm,' she said. Grade 3 or 4 immune-mediated adverse events occurred more frequently in patients in the durvalumab group, she added: 7% vs 4%. The addition of durvalumab did not interfere with the delivery of FLOT in the perioperative setting, and, in the adjuvant phase, 52% of patients in the durvalumab group completed 1 year of therapy, as did 51% of patients in the placebo group, she said. A New Standard? 'To put it simply, the MATTERHORN trial moves the field forward and establishes perioperative durvalumab plus FLOT as the new standard for this patient population,' Samuel Klempner, MD, director of Gastroesophageal Medical Oncology and associate professor at Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, said in comments as the discussant at the plenary session. 'While overall survival is immature, I'm very optimistic that MATTERHORN will show a statistical improvement in overall survival based on the shape of the curves, the strong statistical design, and observations from other phase 3 perioperative gastric trials like RESOLVE and PRODIGY, where longer follow-up improved the hazard ratio and enhanced the significance of the P value,' Klempner said. The RESOLVE trial confirmed the survival advantage of perioperative-S-1 and oxaliplatin (SOX) and adjuvant-SOX compared with the standard adjuvant-postoperative capecitabine-and-oxaliplatin regimen in gastric or gastroesophageal junction cancer. The PRODIGY trial found that neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 followed by surgery and adjuvant S-1 chemotherapy improved progression-free survival over surgery followed by adjuvant S-1 for patients with resectable locally advanced gastric cancer. The MATTERHORN population 'looks like patients in the clinic,' and the similarity in patient dispositions between the study groups was important, said Klempner. 'To me, this says that academic and community oncologists and our surgical colleagues can feel confident that adding durvalumab to FLOT does not impact our ability to complete neoadjuvant FLOT, get to surgery, achieve our zero resection, or complete adjuvant therapy,' he said. 'I also want to stake the claim for D-FLOT as the name for this new standard regimen,' he added to loud applause in the session. 'This is a pivotal trial in upper GI cancer patients in a space that's really been taking center stage in recent years with many recent advances,' Pamela Kunz MD, PhD, director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center in New Haven, Connecticut, said at a press conference before the presentation. 'This is going to change the standard of care for this patient population.' She added that physicians must carefully select patients for durvalumab plus FLOT treatment. 'Can all patients tolerate a four-drug treatment?' Kunz asked. 'The study demonstrated it was reasonably well tolerated, but in terms of the patients in front of us, we need to think about them.' This study was funded by AstraZeneca. Janjigian reported disclosed financial relationships with AbbVie, AmerisourceBergen, Arcus Biosciences, Ask-Gene Pharma, Astellas Pharma, AstraZeneca, Basilea Pharmaceutica, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Clinical Care Options, Daiichi Sankyo, eChinaHealth, ED MedResources, EISAI, Eli Lilly and Co., Genentech, Geneos Therapeutics, GlaxoSmithKline, Guardant Health, H.C. Wainwright & Co., Imedex, Imugene, Inspirna, Lynx Health, Merck, Merck Serono, Mersana Therapeutics, Pfizer, Sanofi Genzyme, Seagen, Silverback Therapeutics, Transcenta, and Zymeworks. Klempner reported relationships with Nuvalent, Merck Serano, Amgen, Astellas Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Daiichi Sankyo UCB Japan, Eisai, Elevation Oncology, Gilead Sciences, I-Mab, Merck, Novartis, SERVIER, Taiho Oncology, Arcus Biosciences, Leap Therapeutics, and Mersana. Disclosures for Kunz were not available at press time.
